| Molecular formula | C101H152N28O22S2 |
|---|
| Molecular weight | 2174.6 g/mol |
|---|
| Registered trials | 9 |
|---|
| PubChem CID | 146675088 |
|---|
What MOTS-c Is
MOTS-c is a mitochondrial-derived peptide studied in laboratory and clinical research settings. It has no FDA-approved label, no approved indication, and no approved brand name. Its chemical identity is catalogued under PubChem CID 146675088, with a molecular formula of C101H152N28O22S2 and a molecular weight of about 2174.6 g/mol. Because it carries no approved label, there is no established mechanism-of-action statement, dosing guidance, or safety labeling to summarize here.
Trial Footprint
Public registries list 9 registered trials referencing MOTS-c. The available samples show varied research contexts rather than a single defined program. One recruiting study is examining high-intensity physical exercise in people with chronic kidney disease, including those on dialysis and those in conservative treatment. A completed trial looked at exercise following a breast cancer diagnosis, and another study involves a cohort focused on deafness-gene screening. These examples indicate that MOTS-c appears across a mix of trial types and research questions rather than a single confirmed clinical use.
FAQ
No. MOTS-c does not have an FDA-approved label, approved indication, or approved brand name. It is studied only in a research context at this time.
MOTS-c is a peptide identified by PubChem CID 146675088, with a molecular formula of C101H152N28O22S2 and a molecular weight of about 2174.6 g/mol. It does not have an established, labeled mechanism of action because no approved label exists.
Public registries list 9 trials that reference MOTS-c. Sample studies include research on exercise in chronic kidney disease, exercise after a breast cancer diagnosis, and a deafness-gene screening cohort.
No adverse event report data was available for MOTS-c at the time this information was compiled. This reflects a gap in available reporting data rather than a confirmed absence of effects.
MOTS-c has no approved indication for any health condition. The trials referencing it are investigational and do not establish that it is effective or safe for any particular use.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication.
Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.
Sources: ClinicalTrials.gov trial registry PubChem compound record
Updated 2026-11-07